Selvita S.A. | Balance Sheet

Fiscal year is January-December. All values PLN Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,298.30
4,877.80
28,806.50
29,094.70
36,124.10
125,449.20
Total Accounts Receivable
4,849.50
10,314.20
17,961.40
16,379.70
19,764.60
42,500.30
Inventories
391.20
706.30
1,174.10
1,403.30
1,591.10
2,781.10
Other Current Assets
651.70
1,411.10
581.80
791.00
2,392.80
2,487.50
Total Current Assets
11,190.70
17,309.50
48,523.80
47,668.60
59,872.60
173,218
Net Property, Plant & Equipment
4,931.60
6,844.80
8,597.00
21,832.60
31,377.10
52,439.70
Total Investments and Advances
-
-
-
3,120.80
2,038.60
22,825.90
Long-Term Note Receivable
162.00
-
-
-
-
-
Intangible Assets
1.10
331.20
2,274.20
6,640.30
2,638.10
2,683.90
Other Assets
-
189.60
196.00
196.00
196.00
196
Total Assets
17,977.30
26,803.30
65,241.80
89,121.10
103,573.50
255,699.70
ST Debt & Current Portion LT Debt
161.50
458.10
301.80
1,804.40
1,823.90
Accounts Payable
3,097.80
5,362.70
3,906.40
6,790.40
9,365.00
Income Tax Payable
-
-
4.50
-
74.50
Other Current Liabilities
8,101.80
9,450.60
12,106.80
10,338.20
15,488.90
Total Current Liabilities
11,361.10
15,271.30
16,319.40
18,933.00
26,752.30
Long-Term Debt
-
176.90
297.60
7,819.50
6,169.80
Provision for Risks & Charges
27.10
27.10
61.40
61.40
1,897.30
Deferred Taxes
1,596.40
2,064.00
5,480.50
9,448.70
6,925.60
Other Liabilities
3,365.00
2,010.30
1,513.40
6,381.60
4,233.10
Total Liabilities
14,848.80
17,549.60
18,362.00
33,409.60
39,578.00
Common Equity (Total)
3,128.50
9,253.60
46,448.40
55,374.60
62,297.90
Total Shareholders' Equity
3,128.50
9,253.60
46,448.40
55,374.60
62,297.90
Total Equity
3,128.50
9,253.60
46,879.80
55,711.50
63,995.60
Liabilities & Shareholders' Equity
17,977.30
26,803.30
65,241.80
89,121.10
103,573.50
Accumulated Minority Interest
-
-
431.40
336.80
1,697.60

About Selvita

View Profile
Address
Park Life Science
Kraków MA 30
Poland
Employees -
Website http://www.selvita.com
Updated 07/08/2019
Selvita SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. It operates through the following segments: Innovation, Services, and Bioinformatics. The Innovation segment focuses on the small-molecule marketing activities of the pharmacological action, which is the next stage of the process of developing the commercialization process.